Business Context and Reporting Period
Ares Capital Corporation (ARCC), a Maryland-based closed-end management investment company, filed this Form 8-K on November 10, 2022. The report details a significant capital raising event executed on the same date.
Key Financial Metrics and Transaction Details
- Shares Issued: 9,200,000 shares of Common Stock ($0.001 par value).
- Offering Price: $18.87 per share.
- Net Proceeds: Approximately $173.2 million after deducting discounts, commissions, and estimated offering expenses.
- Underwriters: Morgan Stanley & Co. LLC, BofA Securities, Inc., and UBS Securities LLC.
- Option Exercise: The offering included 1,200,000 shares purchased by underwriters pursuant to an option granted in the Purchase Agreement.
- Adviser Payment: Ares Capital Management LLC paid the underwriters a supplemental payment of $2,208,000 ($0.24 per share), which is not reimbursed by the Company.
Material Changes
This filing represents a material increase in the Company's equity capital and cash liquidity. The transaction was conducted pursuant to a Purchase Agreement dated November 7, 2022, and registered under Form N-2 (File No. 333-256733). The filing does not provide comparative financial data (revenue, profit, or margins) as it is a current report focused solely on the equity offering.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future performance, or specific risk factors beyond the standard legal disclaimers regarding the Purchase Agreement. The transaction was executed to raise capital, with the Investment Adviser absorbing a portion of the transaction costs via the supplemental payment.
Investor Verification Checklist
- Verify the final number of shares outstanding post-issuance to assess dilution impact.
- Confirm the use of the $173.2 million in net proceeds (e.g., new lending, debt repayment, or general corporate purposes) in subsequent filings.
- Review the full text of the Purchase Agreement (Exhibit 1.1) for any covenants or restrictions associated with the offering.
- Monitor the Company's leverage ratios following the capital injection.